"Just took a look at the Bio Europe slide deck that is now in the posters and presentations section of the Zenith website. Doesn’t seem to be much new and the combination study chart is dated in September, to me that is a little disappointing."

There's always a lag period in the data update. At AGM on 9/12/18, the data was current through 8/22/18. At BIO-Europe on 11/6/18, the data is current through 9/19/18. About a month to go until Biotech Showcase in early January 2019, so we should get more current data then.

Here's a link to the BIO-Europe slide deck. If you look closer, you will see that the BIO-Europe presentation now splits the data into two slides. That is new. The graph on slide 18 is those patients who progressed on abiraterone before starting on the ZEN-3694+enzalutamide combo. The graph on slide 19 is those patients who progressed on enzalutamide before starting ZEN-3694+enzalutamide combo. This latter group is "re-sensitizing" tumors to enzalutamide. In both groups, ZEN-3694 is extending the average time beyond abiraterone or enzalutamide monotherapy standard of care. Also new in BIO-Europe, slides 26 and 27 give new details on the TNBC/ZEN-3694/PARPi trial.

BDAZ